CN1303290A - sPLA2抑制剂酯 - Google Patents

sPLA2抑制剂酯 Download PDF

Info

Publication number
CN1303290A
CN1303290A CN99805672A CN99805672A CN1303290A CN 1303290 A CN1303290 A CN 1303290A CN 99805672 A CN99805672 A CN 99805672A CN 99805672 A CN99805672 A CN 99805672A CN 1303290 A CN1303290 A CN 1303290A
Authority
CN
China
Prior art keywords
methyl
phenylmethyl
indol
oxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99805672A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·丹尼
小J·M·莫林
D·J·萨尔
J·S·肖耶尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1303290A publication Critical patent/CN1303290A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN99805672A 1998-05-01 1999-04-20 sPLA2抑制剂酯 Pending CN1303290A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8387398P 1998-05-01 1998-05-01
US60/083873 1998-05-01

Publications (1)

Publication Number Publication Date
CN1303290A true CN1303290A (zh) 2001-07-11

Family

ID=22181214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99805672A Pending CN1303290A (zh) 1998-05-01 1999-04-20 sPLA2抑制剂酯

Country Status (22)

Country Link
EP (1) EP1073440B1 (cg-RX-API-DMAC10.html)
JP (1) JP4459441B2 (cg-RX-API-DMAC10.html)
KR (1) KR20010071197A (cg-RX-API-DMAC10.html)
CN (1) CN1303290A (cg-RX-API-DMAC10.html)
AT (1) ATE280155T1 (cg-RX-API-DMAC10.html)
AU (1) AU755901B2 (cg-RX-API-DMAC10.html)
BR (1) BR9910149A (cg-RX-API-DMAC10.html)
CA (1) CA2331036A1 (cg-RX-API-DMAC10.html)
DE (1) DE69921314T2 (cg-RX-API-DMAC10.html)
EA (1) EA003277B1 (cg-RX-API-DMAC10.html)
ES (1) ES2230847T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20000738A2 (cg-RX-API-DMAC10.html)
HU (1) HUP0201636A1 (cg-RX-API-DMAC10.html)
ID (1) ID27812A (cg-RX-API-DMAC10.html)
IL (1) IL139203A0 (cg-RX-API-DMAC10.html)
NO (1) NO315940B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ507391A (cg-RX-API-DMAC10.html)
PL (1) PL344571A1 (cg-RX-API-DMAC10.html)
SK (1) SK16332000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200003198T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999056752A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200005561B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
WO2001044185A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
EP2154958A4 (en) * 2007-05-03 2011-05-04 Anthera Pharmaceuticals Inc TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20150335498A1 (en) * 2014-05-22 2015-11-26 The Procter & Gamble Company Heterogenous mass containing foam
US10729600B2 (en) 2015-06-30 2020-08-04 The Procter & Gamble Company Absorbent structure
PL3370664T3 (pl) 2015-11-04 2022-03-07 The Procter & Gamble Company Wyrób chłonny zawierający strukturę chłonną
WO2017079599A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Absorbent structure
WO2017079605A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Method for determining bunch compression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis

Also Published As

Publication number Publication date
NO20005477D0 (no) 2000-10-31
NO20005477L (no) 2000-10-31
WO1999056752A1 (en) 1999-11-11
JP4459441B2 (ja) 2010-04-28
ES2230847T3 (es) 2005-05-01
EP1073440A4 (en) 2002-07-17
AU755901B2 (en) 2003-01-02
DE69921314D1 (de) 2004-11-25
HUP0201636A1 (en) 2002-09-28
DE69921314T2 (de) 2006-02-09
IL139203A0 (en) 2001-11-25
PL344571A1 (en) 2001-11-05
JP2002513761A (ja) 2002-05-14
EP1073440A1 (en) 2001-02-07
BR9910149A (pt) 2001-10-02
AU3652599A (en) 1999-11-23
EA200001141A1 (ru) 2001-04-23
KR20010071197A (ko) 2001-07-28
NO315940B1 (no) 2003-11-17
SK16332000A3 (sk) 2001-06-11
ZA200005561B (en) 2002-01-10
ATE280155T1 (de) 2004-11-15
TR200003198T2 (tr) 2001-03-21
EA003277B1 (ru) 2003-04-24
ID27812A (id) 2001-04-26
NZ507391A (en) 2003-12-19
HRP20000738A2 (en) 2001-10-31
CA2331036A1 (en) 1999-11-11
EP1073440B1 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
CN1067067C (zh) 杂环速激肽受体拮抗物
CN1234705C (zh) 新的羟基吲哚、其作为磷酸二酯酶4抑制剂的应用及其制备方法
CN1098262C (zh) 光学活性的哌啶化合物的酸加成盐和其制备方法
CN1028103C (zh) 哌啶基苯并咪唑类化合物的制备方法
HK1049164A1 (zh) 吲衍生物和其在治療骨質疏鬆中的應用以及其它應用
CN1144522A (zh) 用作降低血胆固醇药物的取代氮杂环丁酮化合物
HU220221B (hu) 1H-Indol-3-ecetsav-hidrazid-származékok, a vegyületeket tartalmazó gyógyászati készítmények és eljárás előállításukra
CN1157375C (zh) 吲哚衍生物及其药物组合物
EP1073440B1 (en) sPLA 2 INHIBITOR ESTERS
CN1025786C (zh) 氨基甲酰基衍生物的制备方法
KR20000069248A (ko) sPLA2 억제제인 페닐 아세트아미드
CN1208333C (zh) 主要用于治疗骨质疏松的吲哚衍生物
EP1202963B1 (en) Spla2 inhibitors
CN1051302C (zh) 3-(吲哚-3-基)丙烯酸衍生物及其用作nmda拮抗剂
CN1022241C (zh) 3-酰基-2-氧代吲哚-1-羧酰胺抗炎剂的前药化合物的制备
CN1699342A (zh) 新的羟基吲哚、其作为磷酸二酯酶4抑制剂的应用及其制备方法
US6274578B1 (en) sPLA2 inhibitor ester
CN1178529A (zh) 用作速激肽受体拮抗剂的杂环取代的哌嗪酮衍生物
WO2007148775A1 (ja) 鎖状アミン化合物
CN1653061A (zh) 喹诺酮羧酸衍生物的制备方法
MXPA00010465A (en) sPLA2
CZ20004051A3 (cs) Ester jako inhibitor sPLA2
HK1033462A (en) Novel processes and intermediates
HK1036974B (en) Indole derivatives and medicinal compositions containing the same
CN1863769A (zh) 氨基吡咯烷衍生物的制备方法和中间体化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication